{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:45:51Z","timestamp":1792518351405,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","aaojournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.ophtha.2016.10.036","type":"journal-article","created":{"date-parts":[[2016,11,24]],"date-time":"2016-11-24T20:17:37Z","timestamp":1480018657000},"page":"352-358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":98,"title":["Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients"],"prefix":"10.1016","volume":"124","author":[{"given":"Ravi","family":"Parikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey R.","family":"Sangaralingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron A.","family":"Adelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilay D.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Barkmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2016.10.036_bib1","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/j.ophtha.2012.05.017","article-title":"Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials","volume":"119","author":"Varma","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.10.036_bib2","unstructured":"Administration FaD. Avastin (bevacizumab) labeling text.\u00a02004. Available at: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/125085s0169lbl; Accessed November 14, 2016."},{"key":"10.1016\/j.ophtha.2016.10.036_bib3","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMp068185","article-title":"The price of sight\u2013ranibizumab, bevacizumab, and the treatment of macular degeneration","volume":"355","author":"Steinbrook","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2016.10.036_bib4","unstructured":"Administration FaD. Aflibercept (Eylea) prescribing information. Available at: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125387lbl.pdf; Accessed November 14, 2016."},{"key":"10.1016\/j.ophtha.2016.10.036_bib5","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.survophthal.2009.02.004","article-title":"Bevacizumab (Avastin) for the treatment of ocular disease","volume":"54","author":"Gunther","year":"2009","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.10.036_bib6","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2016.10.036_bib7","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.10.036_bib8","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Wells","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2016.10.036_bib9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1377\/hlthaff.2014.1032","article-title":"Treating age-related macular degeneration: comparing the use of two drugs among medicare and veterans affairs populations","volume":"34","author":"Pershing","year":"2015","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.ophtha.2016.10.036_bib10","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1377\/hlthaff.2014.0038","article-title":"Optum Labs: building a novel node in the learning health care system","volume":"33","author":"Wallace","year":"2014","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.ophtha.2016.10.036_bib11","unstructured":"OptumLabs. Optumlabs research data assets. Available at: https:\/\/www.optum.com\/content\/dam\/optum\/resources\/productSheets\/5302_Data_Assets_Chart_Sheet_ISPOR.pdf. Accessed March 14,\u00a02015."},{"key":"10.1016\/j.ophtha.2016.10.036_bib12","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ajo.2014.05.014","article-title":"Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries","volume":"158","author":"Lad","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.10.036_bib13","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.ophtha.2016.02.015","article-title":"High variation of intravitreal injection rates and Medicare anti-vascular endothelial growth factor payments per injection in the United States","volume":"123","author":"Erie","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.10.036_bib14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/00002512-200219020-00003","article-title":"Age-related macular degeneration: epidemiology and optimal treatment","volume":"19","author":"la Cour","year":"2002","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ophtha.2016.10.036_bib15","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","article-title":"Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"117","author":"Elman","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.10.036_bib16","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/j.ophtha.2010.08.016","article-title":"Two-year outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study","volume":"117","author":"Nguyen","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.10.036_bib17","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.ophtha.2016.10.036_bib18","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","article-title":"Intravitreal aflibercept for diabetic macular edema","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.10.036_bib19","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ophtha.2015.11.008","article-title":"Intravitreal aflibercept injection in diabetic macular edema patients with and without prior anti-vascular endothelial growth factor treatment: outcomes from the Phase 3 program","volume":"123","author":"Do","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.10.036_bib20","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ophtha.2015.09.035","article-title":"Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study","volume":"123","author":"Clark","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.10.036_bib21","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.ajo.2014.07.027","article-title":"Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study","volume":"158","author":"Ogura","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.10.036_bib22","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ophtha.2014.01.027","article-title":"Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study","volume":"121","author":"Heier","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.10.036_bib23","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1136\/bjo.82.8.971","article-title":"People and eyes: statistical approaches in ophthalmology","volume":"82","author":"Murdoch","year":"1998","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.10.036_bib24","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.10.036_bib25","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1001\/jama.2015.15217","article-title":"Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial","volume":"314","author":"Gross","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ophtha.2016.10.036_bib26","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1056\/NEJMe1500351","article-title":"Treatment choice for diabetic macular edema","volume":"372","author":"Martin","year":"2015","journal-title":"N\u00a0Engl J Med"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642016318346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642016318346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T11:57:37Z","timestamp":1536235057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642016318346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0161642016318346"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2016.10.036","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2016.10.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}